Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
XBiotech Inc. is a biotechnology company involved in the development, production, and commercialization of therapeutic antibodies designed to treat serious human diseases. This company focuses on its proprietary True Human™ antibodies, which are derived from natural human immunity rather than genetically engineered models. The primary purpose of these therapies is to target chronic inflammatory conditions, infectious diseases, and cancer while minimizing potential side effects associated with synthetic antibodies. Founded in 2005 and headquartered in Austin, Texas, XBiotech's research and innovation seek to impact sectors such as healthcare and pharmaceuticals significantly. The company's efforts are centered on advancing medicine by using the human body's natural immune responses to deliver safer and more effective treatments. XBiotech's work represents a pivotal role in the biotechnology landscape as it pushes forward with groundbreaking research aimed at changing therapeutic approaches to human health. By leveraging innovative biotechnology, XBiotech Inc. continues to contribute to developments that could reshape patient care across various medical fields.
$2.32
$0.01 (-0.43%)
Live · 04:26 PM · Twelve Data
ROIC dropped from -16.31% to -26.43%, capital efficiency is deteriorating. Negative free cash flow of -$40M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$40M
▼ -18.2% YoY
Op. Margin
—
ROIC
-26.43%
▼ -10.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$42M
▼ -24.6% YoY
Op. Cash Flow (TTM)
-$34M
▼ -28.9% YoY
Net Debt
-$126M
Net Cash Position
Cash & Equiv.
$126M
Continue Research
XBiotech (XBIT)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, XBiotech scores 16/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
XBiotech scores 16 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -26.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh XBIT's valuation and scores 16/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.